Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic NK Cells with Rituximab in Relapsed NHL or CLL
NCT00625729Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2008
- Primary completion
- Dec 2009
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic natural killer cells in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), sponsored by Masonic Cancer Center. Started Jan 2008; status: terminated.
02
Drugs
allogeneic natural killer cells
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00625729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625729.